NYMOX PHARMACEUTICAL CORP

YTD

ALL

Why Robinhood?

You can watch NYMXF and buy or sell other stocks, ETFs, and their options commission-free!

About NYMXF

Nymox Pharmaceutical Corp. engages in the research and development of products for the aging population. Its products include NicAlert, TobacAlert and Fexapotide Triflutate for the treatment of low-grade localized prostate cancer.

CEO

Paul Averback

CEOPaul Averback

Employees

—

Employees—

Headquarters

Nassau, New Providence

HeadquartersNassau, New Providence

Founded

1995

Founded1995

Employees

—

Employees—

NYMXF Key Statistics

Market cap

7.66M

Market cap7.66M

Price-Earnings ratio

-0.85

Price-Earnings ratio-0.85

Dividend yield

—

Dividend yield—

Average volume

18.65K

Average volume18.65K

High today

$0.081

High today$0.081

Low today

$0.081

Low today$0.081

Open price

$0.081

Open price$0.081

Volume

360.00

Volume360.00

52 Week high

$1.40

52 Week high$1.40

52 Week low

$0.0001

52 Week low$0.0001

People also own

Based on the portfolios of people who own NYMXF. This list is generated using Robinhood data, and it’s not a recommendation.

SNDL

Ideanomics

Tilray Brands

Cenntro Electric Group Li…

Nikola

Camber Energy

NYMOX PHARMACEUTICAL CORP

Why Robinhood?

Nymox Pharmaceutical Corp. engages in the research and development of products for the aging population. Its products include NicAlert, TobacAlert and Fexapotide Triflutate for the treatment of low-grade localized prostate cancer. Show more

NYMXF Key Statistics

People also own

Nymox Pharmaceutical Corp. engages in the research and development of products for the aging population. Its products include NicAlert, TobacAlert and Fexapotide Triflutate for the treatment of low-grade localized prostate cancer.